These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 26152183)

  • 41. Cutaneous toxic effects associated with vemurafenib and inhibition of the BRAF pathway.
    Huang V; Hepper D; Anadkat M; Cornelius L
    Arch Dermatol; 2012 May; 148(5):628-33. PubMed ID: 22431713
    [TBL] [Abstract][Full Text] [Related]  

  • 42. BRAF(V600) mutation levels predict response to vemurafenib in metastatic melanoma.
    Lebbé C; How-Kit A; Battistella M; Sadoux A; Podgorniak MP; Sidina I; Pages C; Roux J; Porcher R; Tost J; Mourah S
    Melanoma Res; 2014 Aug; 24(4):415-8. PubMed ID: 24933605
    [No Abstract]   [Full Text] [Related]  

  • 43. Dupuytren's palmar contracture in women.
    Stahl S; Calif E
    Isr Med Assoc J; 2008 Jun; 10(6):445-7. PubMed ID: 18669144
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Vemurafenib and radiosensitization.
    Boussemart L; Boivin C; Claveau J; Tao YG; Tomasic G; Routier E; Mateus C; Deutsch E; Robert C
    JAMA Dermatol; 2013 Jul; 149(7):855-7. PubMed ID: 23699661
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Treatment patterns and outcomes in BRAF V600E-mutant melanoma patients with brain metastases receiving vemurafenib in the real-world setting.
    Gibney GT; Gauthier G; Ayas C; Galebach P; Wu EQ; Abhyankar S; Reyes C; Guérin A; Yim YM
    Cancer Med; 2015 Aug; 4(8):1205-13. PubMed ID: 25991583
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Progression of KRAS mutant pancreatic adenocarcinoma during vemurafenib treatment in a patient with metastatic melanoma.
    Grey A; Cooper A; McNeil C; O'Toole S; Thompson J; Grimison P
    Intern Med J; 2014 Jun; 44(6):597-600. PubMed ID: 24946815
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A case of vemurafenib-induced keratosis pilaris-like eruption.
    Wang CM; Fleming KF; Hsu S
    Dermatol Online J; 2012 Apr; 18(4):7. PubMed ID: 22559022
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Peyronie's disease and Dupuytren's contracture secondary to topical timolol.
    Oliphant H; Gouws P
    Int Ophthalmol; 2019 Mar; 39(3):683-685. PubMed ID: 29423783
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A phase I, randomized, open-label study of the multiple-dose pharmacokinetics of vemurafenib in patients with BRAF V600E mutation-positive metastatic melanoma.
    Grippo JF; Zhang W; Heinzmann D; Yang KH; Wong J; Joe AK; Munster P; Sarapa N; Daud A
    Cancer Chemother Pharmacol; 2014 Jan; 73(1):103-11. PubMed ID: 24178368
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Phase I/II study of vemurafenib in patients with unresectable or recurrent melanoma with BRAF(V) (600) mutations.
    Yamazaki N; Kiyohara Y; Sugaya N; Uhara H
    J Dermatol; 2015 Jul; 42(7):661-6. PubMed ID: 25884515
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Panniculitis with arthralgia in patients with melanoma treated with selective BRAF inhibitors and its management.
    Zimmer L; Livingstone E; Hillen U; Dömkes S; Becker A; Schadendorf D
    Arch Dermatol; 2012 Mar; 148(3):357-61. PubMed ID: 22250191
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Vemurafenib for the treatment of BRAF mutant metastatic melanoma.
    Martin-Liberal J; Larkin J
    Future Oncol; 2015; 11(4):579-89. PubMed ID: 25686114
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Dupuytren's contracture in a patient with type 2 diabetes mellitus--a case report.
    Puepet FH; Uloko AE; Yiltok SJ; Mijinyawa B
    Niger J Med; 2007; 16(4):384-6. PubMed ID: 18080603
    [TBL] [Abstract][Full Text] [Related]  

  • 54. BRIM-1, -2 and -3 trials: improved survival with vemurafenib in metastatic melanoma patients with a BRAF(V600E) mutation.
    Young K; Minchom A; Larkin J
    Future Oncol; 2012 May; 8(5):499-507. PubMed ID: 22646765
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical development of dabrafenib in BRAF mutant melanoma and other malignancies.
    Gibney GT; Zager JS
    Expert Opin Drug Metab Toxicol; 2013 Jul; 9(7):893-9. PubMed ID: 23621583
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Resveratrol Overcomes Cellular Resistance to Vemurafenib Through Dephosphorylation of AKT in BRAF-mutated Melanoma Cells.
    Luo H; Umebayashi M; Doi K; Morisaki T; Shirasawa S; Tsunoda T
    Anticancer Res; 2016 Jul; 36(7):3585-9. PubMed ID: 27354627
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Vemurafenib-induced pityriasis amiantacea: a case report.
    Bilgiç Ö
    Cutan Ocul Toxicol; 2016 Dec; 35(4):329-31. PubMed ID: 26513697
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Major therapeutic advances in the treatment of metastatic melanoma].
    Mateus C; Robert C
    Bull Cancer; 2012 Jun; 99(6):619-25. PubMed ID: 22652330
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The Hand of Sabazios: Evidence of Dupuytren's Disease in Antiquity and the Origin of the Hand of Benediction.
    Zdilla MJ
    J Hand Surg Asian Pac Vol; 2017 Sep; 22(3):403-410. PubMed ID: 28774258
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Observation on 3 Dupuytren's contractures of the plantar aponeurosis; with a contribution to the etiology of Dupuytren's disease].
    KOHLER CJ
    Z Orthop Ihre Grenzgeb; 1959; 92():118-25. PubMed ID: 14410540
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.